alpelisib - Profile

What are the generic drug sources for alpelisib and what is the scope of freedom to operate?

Alpelisib is the generic ingredient in two branded drugs marketed by Novartis and is included in three NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Alpelisib has seventy-five patent family members in fifty countries.

Summary for alpelisib

International Patents:	75
US Patents:	4
Tradenames:	2
Applicants:	1
NDAs:	3

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for alpelisib

Constraining patent/regulatory exclusivity:

EXPANSION OF THE INDICATION TO INCLUDE PRE AND PERIMENOPAUSAL WOMEN

Dosage:

TABLET;ORAL

Constraining patent/regulatory exclusivity:

TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH SEVERE MANIFESTATIONS OF PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) WHO REQUIRE SYSTEMIC THERAPY

Dosage:

TABLET;ORAL

Dosage:

GRANULES;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for alpelisib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	VIJOICE	alpelisib	GRANULE;ORAL	218466-001	Apr 24, 2024		RX	Yes	Yes
Novartis	VIJOICE	alpelisib	GRANULE;ORAL	218466-001	Apr 24, 2024		RX	Yes	Yes
Novartis	VIJOICE	alpelisib	GRANULE;ORAL	218466-001	Apr 24, 2024		RX	Yes	Yes			Y	Y

EU/EMA Drug Approvals for alpelisib

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novartis Europharm Limited	Piqray	alpelisib	EMEA/H/C/004804Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy (see section 5.1).	Authorised	no	no	no	2020-07-27

International Patents for alpelisib

Country	Patent Number	Title	Estimated Expiration
Cyprus	2020037
Canada	3013845
Brazil	PI0918750

Supplementary Protection Certificates for alpelisib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2331537	2020C/547	Belgium		PRODUCT NAME: ALPELISIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: EU/1/20/1455 20200728
2331537	819	Finland
2331537	PA2020534	Lithuania		PRODUCT NAME: ALPELISIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/20/1455 20200727

Alpelisib: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

Alpelisib (marketed as Piqray) is an oral PI3K-alpha inhibitor developed by Novartis, approved primarily for HR-positive, HER2-negative advanced breast cancer patients harboring PIK3CA mutations. The drug entered the oncology market with substantial growth potential driven by expanding indications, increasing biomarker-driven therapies, and favorable reimbursement policies. This report explores its current market landscape, growth drivers, competitive positioning, and projected financial trajectory, providing an informed basis for investment decisions.

---

What is the Current Market Landscape for Alpelisib?

Market Penetration and Indications

Parameter	Details
Initial Approval	May 2019 by FDA for HR-positive, HER2-negative advanced breast cancer with PIK3CA mutations
Expanded Use	Potential for use in other PIK3CA-mutant tumors (e.g., head and neck, gynecologic cancers); ongoing trial phases
Sales Milestones	Achieved $123 million in global sales in 2022 (Novartis financials)
Market Penetration Rate	Estimated at 15–20% among eligible patients in the US as of 2023

Target Patient Population

• Total Eligible Patients (US, 2023 estimates): Approx. 50,000 annually with HR+/ HER2- advanced breast cancer harboring PIK3CA mutations
• Global Market (anticipated 2025): Approx. 150,000 patients, considering expanding indications and global screening initiatives

Competitive Landscape

Competitors	Description	Market Share (2023)	Status
Alpelisib (Novartis)	First-in-class PI3K-alpha targeted therapy	80% of PIK3CA-mutant niche	Market leader
Other PI3K inhibitors	Buparlisib, taselisib (limited approval, adverse profiles)	<10%	Limited impact
Emerging alternatives	mTOR inhibitors, combination therapies	10%	Growing, but off-label

---

What Are the Market Dynamics Influencing Alpelisib’s Trajectory?

Regulatory and Reimbursement Environment

• FDA and EMA Approvals: Expanded indications in multiple regions aid market access.
• Pricing: List price in the US approx. $13,300/month; rebates and insurance impact actual revenue.
• Coverage Policies: Favorable, with most payers covering PIK3CA testing and targeted therapy for eligible patients.

Biomarker Testing and Diagnostics

• Testing Penetration: Approx. 60-70% of HR+ breast cancer patients are tested for PIK3CA mutations (Source: NCCN Guidelines, 2023).
• Test Companies: Guardant, Foundation, Thermo Fisher—partnerships drive testing volume and thus eligible patient pool.

Market Drivers

1. Increasing Incidence of HR+ Breast Cancer: ~200,000 new cases annually in the US (Source: American Cancer Society, 2023).
2. Biomarker-Driven Therapy Preference: Growing shift towards personalized medicine enhances uptake.
3. Competition and Pipeline Growth: Limited near-term competitors bolster Alpelisib's dominant position.
4. Relapse and Resistance Reduction: Evidence suggests combination approaches may improve long-term outcomes, expanding use cases.

Market Challenges

• Adverse Effects: Hyperglycemia, rash, diarrhea; necessitating management protocols which can impact adherence.
• Pricing Pressures: Increasing payer scrutiny on high-cost therapies.
• Diagnostic Gaps: Low testing rates in certain regions limit market penetration.

---

What Is the Financial Trajectory for Alpelisib?

Revenue Forecasts (2023–2030)

Year	Estimated Global Sales (USD million)	Assumptions	Notes
2023	200	Growth driven by increased testing, approval expansions
2024	300	Indication expansion, increased market penetration
2025	450	Global rollout, combination therapy integration
2026	600	Growth in emerging markets, clinical validation of new combos
2027	750	Broader indication approval (head and neck, gynecological tumors)
2028–2030	1,200–1,500	Peak sales, sustained market share

Note: These estimates account for market growth, adoption rates, and potential pipeline approvals.

Factors Impacting Revenue

• Market Expansion: Indications in other tumor types and line settings.
• Pricing Strategies: Potential discounts, biosimilars, or value-based agreements.
• Patient Testing Rates: Access to PIK3CA mutation testing critically influences treated patient pool.
• Competitive Dynamics: Emergence of combination therapies or novel agents may dilute market share.

Cost Structure Analysis

Category	Estimated Cost %	Details
R&D	~15-20%	Ongoing trials for combination and new indications
Manufacturing	~10%	Scale efficiencies expected
Sales & Marketing	~25%	Education efforts in emerging markets and provider awareness
Regulatory & Distribution	~5%	Approval processes, logistics

Implication: Profit margins expected to remain robust given patent exclusivity until at least 2030.

---

Comparison with Competing or Adjacent Markets

Therapy/Market	Mechanism	Indications	Market Size (2023)	Growth Rate	Key Differentiators
Alpelisib (Piqray)	PI3K-alpha inhibitor	HR+/ HER2- breast cancer, others	$200M (2023) sales estimate	50% CAGR (2023–2025)	First-in-class, specific PIK3CA mutation targeting
Idelalisib (Gilead)	PI3Kδ inhibitor	Hematologic malignancies	Limited (small niche)	Declining	Different isoform
Alpelisib + CDK4/6 inhibitors	Combination therapy	Expanding in breast cancer	Growing	60% CAGR	Synergy prospects

---

Deep Dive: Investment Considerations

• Growth Potential: Driven by indication expansion, increased testing, and global market access.
• Market Risks: High costs, side effect management, off-label competition, and diagnostic gaps.
• Pipeline Position: Supported by ongoing clinical trials in other tumor types and combination therapies.
• Patent and Exclusivity: Patent expected to sustain competitive advantage until mid-2030s.

---

FAQs

1. What markets are most promising for alpelisib’s future growth?
Emerging markets in Asia-Pacific and Europe, along with indications in other PIK3CA-mutant tumors such as head and neck cancers, offer significant growth opportunities.

2. How do adverse effects impact alpelisib's adoption?
Hyperglycemia and rash are managed through protocols, but they can impact patient adherence and limit dose optimization, influencing overall sales.

3. What is the role of companion diagnostics in alpelisib’s market?
PIK3CA mutation testing is essential; expansion of testing facilities and reimbursement policies directly correlate with market expansion.

4. How does alpelisib compare to other PI3K inhibitors?
Alpelisib’s selectivity for PI3K-alpha and better safety profile favor its market position over earlier generation inhibitors with broader toxicity profiles.

5. What are the primary hurdles for alpelisib’s long-term growth?
Competitive pipeline entrants, price sensitivity in healthcare systems, and the need for combination therapy validation.

---

Key Takeaways

• Market Leadership: Alpelisib’s first-to-market status and biomarker-driven approach position it strongly within targeted breast cancer therapies.
• Growth Drivers: Expanded indications, global penetration, better diagnostic integration, and combination therapies will sustain growth.
• Financial Outlook: Revenues are projected to grow from ~$200 million in 2023 to potentially over $1.5 billion by 2030, subject to successful indication expansion and market adoption.
• Strategic Risks: Pricing pressures, side effect management, and diagnostic access are key considerations.
• Investment Edge: Alpelisib offers a high-reward profile driven by innovation in precision oncology, with patent protections extending into the late 2030s.

---

References

[1] Novartis Financial Reports, 2022.
[2] FDA & EMA Approval Announcements, 2019–2023.
[3] NCCN Guidelines, 2023.
[4] American Cancer Society, Cancer Facts & Figures, 2023.
[5] Market Research Reports on Oncology Therapeutics, 2023.